

Establishing leadership in
the rapidly accelerating
respiratory remote digital
monitoring environment

APRIL 2021

adherium

- Rapid evolution of telehealth & remote digital monitoring, accelerated by COVID and new reimbursement programs
- Well placed with strategy development beyond adherence alone, toward multi-sensor respiratory management ecosystem
- Potential for software platform leverage with established data portal capability
- Good progress made with core data portal refresh & development of physiologically enabled adherence monitoring devices
- Progress being made with existing commercial partners & >10 ongoing new partner discussions advancing
- Fundraise initiated to progress business toward breakeven target

\$18m fundraise to progress beyond 2021 commercial evaluations

opportunity

Telehealth & remote digital management of patients transformed in last 24 months due to introduction of reimbursement codes & impact of COVID pandemic

COVID has changed expectations on care delivery

- Estimates of pre-pandemic awareness of telehealth benefits has risen from 24% to 80%³
- Estimates over 1/3 of ambulatory visits could be done remotely³
- Telehealth³ offers possibility for over 50 million Americans in remote areas access to routine healthcare
- 11% consumers using telehealth in 2019²
- 76% consumers indicated they were highly or moderately likely to use telehealth going forwards²
- 50-175x reported increase in health systems & practices reported use of telehealth²
- Estimated \$250b market size²

Reimbursement availability now a catalyst for adoption

- Introduction of Medicare reimbursement for Remote Patient Monitoring opened the professional market by creating clear financial incentives & a path to payment for physicians
- This was a 'watershed' moment; Medicare & Medicaid cover 1/3 of the patient universe with insurers covering remaining 2/3 typically following Medicare / Medicaid lead in coverage & payment

"...in April 2020, nearly half (43.5%) of Medicare primary care visits were provided through telehealth compared with less than one percent (0.1%) in February before the public health emergency [Covid-19]"¹

1. <https://www.hhs.gov/about/news/2020/07/28/hhs-issues-new-report-highlighting-dramatic-trends-in-medicare-beneficiary-telehealth-utilization-amid-covid-19.html>


2. <https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality#>

3. Lisa Gill JPM insights commentary <https://www.jpmorgan.com/solutions/cib/insights/health-care-conference#insights>

strategy

Opportunity NOW to transform Adherium to lead commercially valuable integrated management solutions

respiratory digital management ecosystem



Business with range of digital inhaler sensors & portal platform for adherence monitoring

evolution



Adherium

Now

Adherium Hailie® Sensors
Peak Flow Meter

Business based on a respiratory ecosystem providing a portal & software platform with architecture for the integration of proprietary & 3rd party digital sensors, connected devices & data management systems

Sensors
Portal
Adherence

Revenue generation
Healthcare providers & payers
Partner Summatix / Planet Innovation
for data aggregation / analysis
Population risk assessment

Phase 2

Assets from current and future discussions

Assets from current relationships

Adherium Hailie® Sensors
Peak Flow Meter

Phase 1

Assets from current relationships

Adherium Hailie® Sensors
Peak Flow Meter

Existing Partners



- Phase 1 training completed
- Pilot Program of evaluations in specialist Asthma centers initiated
- Pilot read outs expected Q2 CY2021



- Initial workflow assessment complete
- Modifications made to patient materials & app in response to feedback
- Rescue inhaler patient population data collection ongoing



- Primary activity from clinical trials & development contracts
- Four clinical studies underway using Adherium sensors
- Development projects upgrading patient user experience initiated

Current Portfolio

Sensors

- Physiologically enabled sensor development progressing well (plan increases asthma/COPD device market coverage from 56% to 80% by US medication volume by H1 CY2022)
- Physiological measure proof of concept transferred to commercial product design
- Submission of first 510(k) of physiological enabled sensor expected Q1 CY 2021
- Finalist in "Australia by Design" Innovation Award TV series

Software

- Migration of platform to Microsoft Azure® completed to deliver capacity & capability for scale-up
- Peak Flow meter integration expected early Q2 CY2021 as first step in ecosystem build
- App & portal upgrades enhanced user experience & data presentation for patients & physicians
- System architecture design allows integration of third party devices into the platform

strategy

Rapid acceleration in telehealth & digital monitoring reflected in increased partnering opportunities strengthening revenue stream potential with >10 ongoing commercial partnering engagements currently progressing at C suite level

| Partner Type | Disease/Population Management Partners | CDMO's | Pharmaceutical Companies |
|----------------------|--|--|--|
| Rationale | Connected Health Solution PERS & RPM Employer / Commercial Payers Plans Integrated Managed Care Consortia Telemedicine / Virtual Care Providers On-Line Pharmacies | Pharma / Biotech Medical Devices Inhaled Pharmaceuticals | Inhaled Pharmaceuticals |
| Product Range | Series of ongoing discussions in North America to provide Hailie® digital sensors & portal reporting to enhance existing care provision & remote patient monitoring | Potential to integrate Hailie® digital sensor technology into CDMO products & leverage Adherium portal with CDMO customers | Potential to provide complementary digital sensors alongside sponsor products & leverage Adherium portal |
| Revenue Model | Adherium Sensor sales Software licence fee (SaaS & PaaS) Data licence fee | | |

strategy

Ecosystem evolution enhances overall product proposition to end clinical providers & payors with multiple longitudinal data points, leverages portal platform, & extends revenue stream potential for individual & combination of assets beyond adherence alone

| Ecosystem Build | Initial ecosystem of Adherium sensors plus 3rd Party Devices & Apps | | | | Second Phase under investigation | |
|-----------------|--|--|--|--|--|--|
| Product | Adherium Sensors | Peak Flow Meter | Spirometer | Wheeze Analysis | Capnography COPD | COPD exacerbations predictor |
| Rationale | Monitors patient adherence (frequency, date & time); inhaler technique; physiological measures* | Measures maximum speed of expiration, assesses ability to breath air out as an assessment of airway obstruction. Primarily used in asthma. Complementary diagnostic assessment of control with adherence. Portal platform leverage | Measures lung function. Volume of air inspired & expired. Primarily for COPD patients Complementary diagnostic assessment of disease control with adherence Portal platform leverage | Measures wheeze a symptom of airway obstruction in asthma. Complementary diagnostic in conjunction with other parameters such as adherence, peak flow & lung function | Extends offering in COPD & supports predictive analysis of exacerbations. Application in asthma under investigation | Extends offering in COPD & supports predictive analysis of exacerbations |
| Product Range | 6 sensors available today with 56% coverage, build to 9 with physiological data capture giving 80% coverage in H1 CY2022 | Peak flow sensor integration progressing. Commercially available with portal integration from H1 CY2021 | Digital device integration assessment progressing. Target commercially available with portal integration from H2 CY2021 | Initial pharmacy pilot & clinical trial evaluation being initiated in Australia | Point of care device with physician data reporting | App with integration to peak flow data & biomarker data |
| Revenue Model | Adherium Sensor sales Software licence fee (SaaS & PaaS) Data licence fee | | | | | |

Significant potential for further ecosystem sensor device integration including digitised spacers, nebulizers, OPEP mucus secretion devices

1 CY Q3 2020 – Q2 2021

Initial partner model establishment/proof of concept

- Validate channel partners
- Test operational model
- Validate business model
- Limited initial sensor volumes & orders
- Appointment of key leadership roles in US & CTO in Australia
- Contracting new industry partners
- Establish ecosystem framework & initial sensor integration assessment

2 CY Q2 2021 – Q4 2021

Partner scale-up in US with revenue traction

- Scale-up of HGE & Monaghan; initiate industry partner activity
- Progressive revenue growth
- Increase penetration in COPD
- First wave sensors with physiological measures
- Complete market launch of full range of physiological enabled sensor
- Limited highly selective ex-US activity
- Pilot ecosystem build with early roll out of 3 new integrated sensors

3 CY 2022

Full expansion & platform leverage in US & ex-US

- Accelerated US commercialisation with full portfolio
- Potential expanded scale-up ex-US
- Assess next wave device development e.g. nebulisers/integrated sensors
- Potential multi-provider data integration leverage & monetisation
- Scale ecosystem with further new sensors with progressive revenue growth

\$18m fundraise to progress beyond 2021 commercial evaluations

Disclaimer and forward looking statement


The material contained herein is of a general nature & has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or potential opportunities.

This presentation may contain budget information, forecasts & forward-looking statements in respect of which there is NO guarantee of future performance & which of themselves involve significant risks (both known & unknown). Actual results & future outcomes will in all likelihood differ from those outlined herein.

Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” & similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding market size, future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks & uncertainties, many of which are difficult to predict & generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information & statements. These risks & uncertainties include, but are not limited to: (i) the possible delays in & the outcome of product development, (ii) risks relating to possible partnering or other like arrangements, (iii) the potential for delays in regulatory approvals, (iv) the unknown uptake & market penetration of any potential

commercial products & (vi) other risks & uncertainties related to the Company’s prospects, assets / products & business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing & commercialising medical devices & related services. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, & we do not undertake any obligation to revise & disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Additionally there are a number of factors, both specific to Adherium & of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward-looking statements will be realised.



APRIL 2021

adherium